Vol 2, No 2 (June 16, 2013): Translational Andrology and Urology

Editorials

Refining treatment for the men who need it: lessons from the PIVOT trial

Michael R. Abern, Matvey Tsivian, Thomas J. Polascik

PDF Pages: 82-84 Full Text (3166) Open Access

Does patient-tailored immunotherapy pave the way for new renal cell carcinoma treatment perspectives?

Ilse Van Brussel, Amaryllis H. Van Craenenbroeck, Dorien M. Schrijvers, Nathalie Cools

PDF Pages: 85-88 Full Text (4616) Open Access

Immunotherapy in renal cell cancer: the more the merrier?

Jorge Camarero, Sol Ruiz

PDF Pages: 89-91 Full Text (2931) Open Access

Enzalutamide (formerly MDV3100) prolongs survival in docetaxel-pretreated castration-resistant prostate cancer patients

Matthias M. Heck, Jürgen E. Gschwend, Margitta Retz

PDF Pages: 92-93 Full Text (3900) Open Access

Original Articles

Treatment of failed vasectomy reversal using a microsurgical two-layer anastomosis technique

Bingkun Li, Guoling Chen, Xiang Wang

PDF Pages: 94-98 Full Text (Video) (9482) Open Access

VEGF is associated with the poor survival of patients with prostate cancer: a meta-analysis

Ping Zhan, Ya-Nan Ji, Li-Ke Yu

PDF Pages: 99-105 Full Text (7344) Open Access

Review Article

Exogenous testosterone: a preventable cause of male infertility

Lindsey E. Crosnoe, Ethan Grober, Dana Ohl, Edward D. Kim

PDF Pages: 106-113 Full Text (107030) Open Access

Research Highlights

Tivozanib: a novel VGFR inhibitor for kidney cancer

Helen Boyle

PDF Pages: 114-116 Full Text (3044) Open Access

Identification of biomarkers in pazopanib treated patients with renal cell carcinoma

Amy M Pick, Zara Risoldi Cochrane

PDF Pages: 117-118 Full Text (2543) Open Access

Enzalutamide: the emperor of all anti-androgens

Emmanuel S. Antonarakis

PDF Pages: 119-120 Full Text (5449) Open Access